No supplier or customer ties in IMDX's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Nothing on the wire mentions IMDX yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How IMDX has moved on past release days vs its typical ±3.6% day, and how often it closed up. Computed from daily closes — not a forecast.